The Hepatology Program at the University of Michigan is one of the largest and most well-established programs in the country. We specialize in the diagnosis and management of acute liver failure, hepatitis B and C, autoimmune liver disease, primary biliary cirrhosis, primary sclerosing cholangitis, non-alcoholic fatty liver disease, cirrhosis, and complications of portal hypertension, hepatocellular carcinoma and liver transplantation.
Our mission is to provide state-of-the-art, innovative, and compassionate care to patients affected by liver diseases through general hepatology, viral hepatitis, liver tumor, and liver transplantation clinics. As part of this mission, we provide multidisciplinary care so patients can be evaluated by physicians from all appropriate disciplines during a single visit. In addition, we are actively engaged in clinical research including novel therapies, improved diagnostic modalities, and better biomarkers and predictors of outcome. All patients seen in any of our Hepatology Clinics who are potential candidates for new therapies and other research protocols are referred for participation in clinical trials.
Headed by Anna Lok, MD, FRCP, the Hepatology Program includes thirteen faculty members with expertise in a wide variety of liver diseases. Our faculty plays key roles in multiple NIH-sponsored clinical research networks, including acute liver failure, biomarkers for early diagnosis of hepatocellular carcinoma, drug-induced liver injury, hepatitis B, Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial and Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL).
We are also involved in many clinical trials supported by pharmaceutical companies. These trials evaluate new therapies for various liver diseases including hepatitis B and C, fatty liver, and hepatocellular carcinoma.